Interventions for Old World cutaneous leishmaniasis

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 11, 2017, Pages

  Heras Mosteiro, Julio ^a,b   Monge Maillo, Begoña ^b   Pinart, Mariona ^c   Lopez Pereira, Patricia ^b   Garcia Carrasco, Emely ^d   Campuzano Cuadrado, Pedro ^a   Royuela, Ana ^e   Mendez Roman, Irene ^c   López Vélez, Rogelio ^b  

^a UNIVERSIDAD REY JUAN CARLOS   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d National Referral Centre for Tropical Diseases   (Spain)

^e HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ITRACONAZOLE; PAROMOMYCIN; PLACEBO; ANTIINFECTIVE AGENT; ANTIPROTOZOAL AGENT; OINTMENT BASE;

ABDOMINAL PAIN; DERMATITIS; DIZZINESS; DRUG EFFICACY; FOLLOW UP; HEADACHE; HISTOPATHOLOGY; HUMAN; IMMUNOCOMPROMISED PATIENT; LIVER DYSFUNCTION; MICROBIOLOGICAL PARAMETERS; NAUSEA; OINTMENT; OLD WORLD SKIN LEISHMANIASIS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN DEFECT; SKIN LEISHMANIASIS; SKIN PAIN; SKIN REDNESS; SYSTEMATIC REVIEW; VESICULAR RASH; ALTERNATIVE MEDICINE; ANIMAL; CRYOTHERAPY; HEAT; LEISHMANIA MAJOR; LEISHMANIA TROPICA; LOW LEVEL LASER THERAPY; META ANALYSIS; PHOTOCHEMOTHERAPY; THERAPEUTIC USE; ADULT; FAR EAST; FEMALE; MALE; MIDDLE AGED; MIDDLE EAST; PROCEDURES;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTIPROTOZOAL AGENTS; COMPLEMENTARY THERAPIES; CRYOTHERAPY; HOT TEMPERATURE; HUMANS; ITRACONAZOLE; LASER THERAPY; LEISHMANIA MAJOR; LEISHMANIA TROPICA; LEISHMANIASIS, CUTANEOUS; PAROMOMYCIN; PHOTOCHEMOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; ADULT; FAR EAST; FEMALE; MALE; MIDDLE AGED; MIDDLE EAST; OINTMENT BASES;

EID: 85034265476     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD005067.pub4     Document Type: Review

References (255)

1. Adam I, Hagelnur A. Artesunate plus sulfamethoxypyrazine/pyrimethamine for the treatment of cutaneous leishmaniasis: a double-blind, placebo-controlled clinical trial. International Journal of Antimicrobial Agents 2009;34(4):380-1. [PUBMED: 19409761 ]2831868
2. al-Fouzan AS, al-Saleh QA, Najem NM, Rostom AI. Cutaneous leishmaniasis in Kuwait. Clinical experience with itraconazole. International Journal of Dermatology 1991;30(7):519-21. [PUBMED: 1663089]2831870
3. Al Hamdi K, Awad AH, Moker HM. Evaluation of intralesional 0.2% ciprofloxacin as a treatment for cutaneous leishmaniasis. Eastern Mediterranean Health Journal 2010;16(1):89-93. [PUBMED: 20214164]2831872
4. Alkhawajah AM, Larbi E, al-Gindan Y, Abahussein A, Jain S. Treatment of cutaneous leishmaniasis with antimony: intramuscular versus intralesional administration. Annals of Tropical Medicine and Parasitology 1997;91(8):899-905. [PUBMED: 9579209]2831874
5. Alrajhi AA, Ibrahim EA, De Vol EB, Khairat M, Faris RM, Maguire JH. Fluconazole for the treatment of cutaneous leishmaniasis caused by leishmania major. New England Journal of Medicine 2002;346(12):891-5. [PUBMED: 11907288]2831876
6. Alsaleh QA, Dvorak R, Nanda A. Ketoconazole in the treatment of cutaneous leishmaniasis in Kuwait. International Journal of Dermatology 1995;34(7):495-7. [PUBMED: 7591417]2831878
7. Aronson NE, Wortmann GW, Byrne WR, Howard RS, Bernstein WB, Marovich MA, et al. A randomized controlled trial of local heat therapy versus intravenous sodium stibogluconate for the treatment of cutaneous Leishmania major infection. PLoS Neglected Tropical Diseases 2010;4(3):e628. [PUBMED: 20231896]2831880
8. Asilian A, Jalayer T, Whitworth JA, Ghasemi RL, Nilforooshzadeh M, Olliaro P. A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paramomycin) ointment for treatment of cutaneous leishmaniasis in Iran. American Journal of Tropical Medicine and Hygiene 1995;53(6):648-51. [PUBMED: 8561269]2831882
9. Asilian A, Jalayer T, Nilforoosshzadeh M, Ghassemi RL, Peto R, Wayling S, et al. Treatment of cutaneous leishmaniasis with aminosidine (paromomycin) ointment: double-blind, randomized trial in the Islamic Republic of Iran. Bulletin of the World Health Organization 2003;81(5):353-9. [PUBMED: 12856053]2831884
10. Asilian A, Sadeghinia A, Faghihi G, Momeni A. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryothrapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis. International Journal of Dermatology 2004;43(4):281-3. [PUBMED: 15090013]2831886
11. Asilian A, Sharif A, Faghihi G, Enshaeieh Sh, Shariati F, Siadat AH. Evaluation of CO laser efficacy in the treatment of cutaneous leishmaniasis. International Journal of Dermatology 2004;43(10):736-8. [PUBMED: 15485530]2831888
12. Asilian A, Davami M. Comparison between the efficacy of photodynamic therapy and topical paromomycin in the treatment of Old World cutaneous leishmaniasis: a placebo-controlled, randomized clinical trial. Clinical & Experimental Dermatology 2006;31(5):634-7. [PUBMED: 16780497]2831890
13. Asilian A, Omrani Sh, Nilforoushzadeh MA. Comparing the effects of topical miltefosine and glucantime in treatment of cutaneous leishmaniasis. Journal of Isfahan Medical School 2014;31(269):2257-63. 2831892
14. Ben Salah A, Zakraoui H, Zaatour A, Ftaiti A, Zaafouri B, Garraoui A, et al. A randomized, placebo-controlled trial in Tunisia treating cutaneous leishmaniasis with paromomycin ointment. American Journal of Tropical Medicine and Hygiene 1995;53(2):162-6. [PUBMED: 7677218]2831894
15. Ben Salah A, Buffet PA, Morizot G, Ben Massoud N, Zâatour A, Ben Alaya N, et al. WR279, 396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study. PLoS Neglected Tropical Diseases 2009;3(5):e432. [PUBMED: 19415122]2831896
16. Ben Salah A, Ben Messaoud N, Guedri E, Zaatour A, Ben Alaya N, Bettaieb J, et al. Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. New England Journal of Medicine 2013;368(6):524-32. [PUBMED: 23388004 ]2831898
17. Bumb RA, Prasad N, Khandelwal K, Aara N, Mehta RD, Ghiya BC, et al. Long-term efficacy of single-dose radiofrequency-induced heat therapy vs. intralesional antimonials for cutaneous leishmaniasis in India. British Journal of Dermatology 2013;168(5):1114-9. [PUBMED: 23298394]2831900
18. Daie Parizi MH, Karvar M, Sharifi I, Bahrampour A, Heshmat Khah A, Rahnama Z, et al. The topical treatment of anthroponotic cutaneous leishmaniasis with the tincture of thioxolone plus benzoxonium chloride (Thio-Ben) along with cryotherapy: A single-blind randomized clinical trial. Dermatologic Therapy 2015;28(3):140-6. [PUBMED: 25847678]7068478
19. Dandashi A. Treatment of cutaneous leishmaniasis with fluconazole: a randomized double-blind, placebo-controlled trial. Journal of the European Academy of Dermatology and Venereology: JEADV 2005;19(Suppl 2):43. 2831902
20. Dastgheib L, Naseri M, Mirashe Z. Both combined oral azithromycin plus allopurinol and intramuscular Glucantime yield low efficacy in the treatment of Old World cutaneous leishmaniasis: a randomized controlled clinical trial. International Journal of Dermatology 2012;51(12):1508-11. [PUBMED: 23171020]2831904
21. Dogra J, Aneja N, Lal BB, Mishra SN. Cutaneous leishmaniasis in India: Clinical experience with itraconazole (R51 211 Janssen). International Journal of Dermatology 1990;29(9):661-2. [PUBMED: 2177041]2831906
22. Dogra J. A double-blind study on the efficacy of oral dapsone in cutaneous leishmaniasis. Transactions of the Royal Society of Tropical Medicine and Hygiene 1991;85(2):212-3. [PUBMED: 1887473]2831908
23. Dogra J. Cutaneous leishmaniasis in India: evaluation of oral drugs (dapsone versus itraconazole). European Journal of Dermatology 1992;2:568-9. 2831910
24. Dogra J, Saxena VN. Itraconazole and leishmaniasis: a randomised double-blind trial in cutaneous disease. International Journal for Parasitology 1996;26(12):1413-5. [PUBMED: 9024895]2831912
25. Ejaz A, Qadir SNUR, Malik N, Bari AU. Comparison of low-dose meglumine antimoniate/ allopurinol combination therapy with full dose meglumine antimoniate alone in the treatment of cutaneous leishmaniasis - A randomized controlled trial. Journal of Pakistan Association of Dermatologists 2014;24(2):108-114. [EMBASE: 373774478]2831914
26. El-Sayed M, Anwar AE. Intralesional sodium stibogluconate alone or its combination with either intramuscular sodium stibogluconate or oral ketoconazole in the treatment of localized cutaneous leishmaniasis: a comparative study. Journal of the European Academy of Dermatology and Venereology: JEADV 2010;24(3):335-40. [PUBMED: 19744259]2831916
27. Emad M, Hayati F, Fallahzadeh MK, Namazi MR. Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: a randomized clinical trial. Journal of the American Academy of Dermatology 2011;64(3):606-8. [PUBMED: 21315963]2831918
28. Esfandiarpour I, Alavi A. Evaluating the efficacy of allopurinol and meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis. International Journal of Dermatology 2002;41(8):521-4. [PUBMED: 12207774]2831920
29. Faghihi G, Tavakoli-kia R. Topical paromomycin vs intralesional meglumine antimoniate in cutaneous leishmaniasis. Clinical and Experimental Dermatology 2003;28(1):13-6. [PUBMED: 12558620]2831922
30. Farajzadeh S, Esfandiarpour I, Haghdoost AA, Mohammadi S, Mohebbi A, Mohebbi E, Mostafavi M. Comparison between combination therapy of oral terbinafine and cryotherapy versus systemic meglumine antimoniate and cryotherapy in cutaneous leishmaniasis: a randomized clinical trial. Iranian Journal of Parasitology 2015;10(1):1-8. [PUBMED: 25904940]2831924
31. Fekri A, Rahnama Z, Khalili M, Dookhani AP, Khazaeli P, Beigi KB. The efficacy of co-administration of topical niosomal dapsone gel and intralesional injection of glucantime in cutaneous leishmaniasis in comparison with cryotherapy plus intralesional injection of glucantime. Journal of Kerman University of Medical Sciences 2015;22(2):117-32. [PUBMED: 603502875]2831926
32. Firooz A, Khatami A, Khamesipour A, Nassiri-Kashani M, Behnia F, Nilforoushzadeh M, et al. Intralesional injection of 2% zinc sulphate solution in the treatment of acute Old World cutaneous leishmaniasis: a randomized, double-blind, controlled clinical trial. Journal of Drugs in Dermatology 2005;4(1):73-9. [PUBMED: 15696988]2831928
33. Firooz A, Khamesipour A, Ghoorchi MH, Nassiri-Kashani M, Eskandari SE, Khatami A, et al. Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial. Archives of Dermatology 2006;142(12):1575-9. [PUBMED: 17178983 ]2831930
34. Gholami A, Khamesipour A, Momeni A, Ghazanfari T, Nilforoushzadeh MA, Darajeh Z, et al. Treatment of cutaneous leishmaniasis with 5% garlic cream: a randomized, double-blind study. Iranian Journal of Dermatology 2000;3(3):2-6. [CENTRAL: CN-00454251]2831932
35. Harms G, Chehade AK, Douba M, Roepke M, Mouakeh A, Rosenkaimer F, et al. A randomized trial comparing a pentavalent antimonial drug and recombinant interferon-gamma in the local treatment of cutaneous leishmaniasis. Transactions of the Royal Society of Tropical Medicine and Hygiene 1991;85(2):214-6. [PUBMED: 1909469]2831934
36. Iraji F, Vali A, Asilian A, Shahtalebi M, Momeni AZ. Comparison of intralesionally injected zinc sulphate with meglumine antimoniate in the treatment of acute cutaneous leishmaniasis. Dermatology 2004;209(1):46-9. [PUBMED: 15237267]2831936
37. Iraji F, Sadeghinia A. Efficacy of paromomycin ointment in the treatment of cutaneous leishmaniasis: results of a double-blind, randomized trial in Isfahan, Iran. Annals of Tropical Medicine and Parasitology 2005;99(1):3-9. [PUBMED: 15701249]2831938
38. Jaffar H. Rifampicin in cutaneous leishmaniasis - a therapeutic trial in Saudi Arabia. Journal of Pakistan Association of Dermatologists 2006;16(1):4-9. [EMBASE: 44265597]2831940
39. Jaffary F, Nilforoushzadeh MA, Ansari N, Rahimi M. Treatment of cutaneous leishmaniasis: cassia fistula fruit gel-intralesional glucantime Vs. placebo gel- intralesional glucantime combination. Tehran University Medical Journal 2010;67(10):705-11. 2831942
40. Jaffary F, Nilforoushzadeh MA, Tavakoli N, Zolfaghari B, Shahbazi F. The efficacy of Achilles millefolium topical gel along with intralesional injection of glucantime in the treatment of acute cutaneous leishmaniasis major. Advanced Biomedical Research 2014;3:111. [PUBMED: 24804185 ]2831944
41. Jaffary F, Nilforoushzadeh MA, Moradi S, Derakhshan R, Ansari N. Concentrated extracts of Cassia fistula versus intralesional injection of meglumine antimoniate in treatment of acute cutaneous leishmaniasis. Journal of Skin and Stem Cell 2014;1(1):e16631. [EMBASE: 604236618]2831946
42. Jebran AF, Schleicher U, Steiner R, Wentker P, Mahfuz F, Stahl HC, et al. Rapid healing of cutaneous leishmaniasis by high-frequency electrocauterization and hydrogel wound care with or without DAC N-055: a randomized controlled phase IIa trial in Kabul. PLoS Neglected Tropical Diseases 2014;8(2):e2694. [PUBMED: 24551257 ]2831948
43. Jowkar F, Dehghani F, Jamshidzadeh A. Is topical nitric oxide and cryotherapy more effective than cryotherapy in the treatment of old world cutaneous leishmaniasis?. Journal of Dermatological Treatment 2012;23(2):131-5. [PUBMED: 20964568 ]2831950
44. Kashani MN, Sadr B, Nilforoushzadeh MA, Arasteh M, Babakoohi S, Firooz A. Treatment of acute cutaneous leishmaniasis with intralesional injection of meglumine antimoniate: comparison of conventional technique with mesotherapy gun. International Journal of Dermatology 2010;49(9):1034-7. [PUBMED: 20883265 ]2831952
45. Khatami A, Rahshenas M, Bahrami M, Ghoorchi MH, Eskandari SE, Sharifi I, et al. Miltefosine in treatment of cutaneous leishmaniasis: a randomized controlled trial (Poster P-31). 6th International Dermato-Epidemiology Association Congress, Malmo, Sweden, 26-28 August 2012. British Journal of Dermatology 2012;167(2):e23. [EMBASE: 71050777]2831954
46. Khatami A, Talaee R, Rahshenas M, Khamesipour A, Mehryan P, Tehrani S, et al. Dressings combined with injection of meglumine antimoniate in the treatment of cutaneous leishmaniasis: a randomized controlled clinical trial. PloS One 2013;8(6):e66123. [PUBMED: 23826087]2831956
47. Kochar DK, Aseri S, Sharma BV, Bumb RA, Mehta RD, Purohit SK. The role of rifampicin in the management of cutaneous leishmaniasis. QJM: Monthly Journal of the Association of Physicians 2000;93(11):733-7. [PUBMED: 11077029]2831958
48. Kochar DK, Saini G, Kochar SK, Sirohi P, Bumb RA, Mehta RD, et al. A double blind, randomised placebo controlled trial of rifampicin with omeprazole in the treatment of human cutaneous leishmaniasis. Journal of Vector Borne Diseases 2006;43(4):161-7. [PUBMED: 17175700]2831960
49. Larbi EB, al-Khawajah A, al-gindan Y, Jain S, Abahusain A, al-Zayer A. A randomized, double-blind, clinical trial of topical clotrimazole versus mizonazole for treatment of cutaneous leishmaniasis in the eastern province of Saudi Arabia. American Journal of Tropical Medicine and Hygiene 1995;52(2):166-8. [PUBMED: 7872446]2831962
50. Layegh P, Yazdanpanah MJ, Vosugh EM, Pezeshkpoor F, Shakeri MT, Moghiman T. Efficacy of azitromycin versus systemic meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis. American Journal of Tropical Medicine and Hygiene 2007;77(1):99-101. [PUBMED: 17620637]2831964
51. Layegh P, Pezeshkpoor F, Soruri AH, Naviafar P, Moghiman T. Efficacy of cryotherapy versus intralesional meglumine antimoniate (Glucantime) for treatment of cutaneous leishmaniasis in children. American Journal of Tropical Medicine and Hygiene 2010;80(2):172-5. [PUBMED: 19190206]2831966
52. Layegh P, Rajabi O, Jafari MR, Emamgholi Tabar Malekshah P, Moghiman T, Ashraf H, et al. Efficacy of topical liposomal amphotericin B versus intralesional meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis. Journal of Parasitology Research 2011;2011:656523. [DOI: 10.1155/2011/656523; PUBMED: 22174993 ]2831968
53. Lynen L, Van Damme W. Local application of diminazene aceturate: an effective treatment for cutaneous leishmaniasis?. Annales de la Société Belge de Médecine Tropicale 1992;72(1):13-9. [PUBMED: 1567264]2831970
54. Maleki M, Karimi G, Tafaghodi M, Raftari S, Nahidi Y. Comparison of intralesional two percent zinc sulfate and glucantime injection in treatment of acute cutaneous leishmaniasis. Indian Journal of Dermatology 2012;57(2):118-22. [PUBMED: 22615508]2831972
55. Mapar MA, Omidian M. Intralesional injections of metronidazole versus meglumine antimoniate for the treatment of cutaneous leishmaniasis. Jundishapur Journal of Microbiology 2010;3(2):79-83. [EMBASE: 2010406291]2831974
56. Mashhood AA, Hussain K. Efficacy of allopurinol compared with pentostam in the treatment of old world cutaneous leishmaniasis. Journal of the College of Physicians and Surgeons--Pakistan: JCPSP 2001;11(6):367-70. [EMBASE: 2001264054]2831976
57. Mohebali M, Fotouhi A, Hooshmand B, Zarei Z, Akhoundi B, Rahnema A, et al. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran. Acta Tropica 2007;103(1):33-40. [PUBMED: 17586452]2831978
58. Momeni AZ, Jalayer T, Emamjomeh M, Bashardost N, Ghassemi RL, Meghdadi M, et al. Treatment of cutaneous leishmaniasis with itraconazole. Randomized doubl-blind study. Archives of Dermatology 1996;132(7):784-6. [PUBMED: 8678570]2831980
59. Momeni AZ, Reiszadae MR, Aminjavaheri M. Treatment of cutaneous leishmaniasis with a combination of allopurinol and low-dose meglumine antimoniate. International Journal of Dermatology 2002;41(7):441-3. [PUBMED: 12121563]2831982
60. Momeni AZ, Aminjavaheri M, Omidghaemi MR. Treatment of cutaneous leishmaniasis with ketoconazole cream. Journal of Dermatological Treatment 2003;14(1):26-9. [PUBMED: 12745852]2831984
61. Mostafavi SA, Shatalebi MA, Attar AM, Hejazi H, Mottaghinejad A, Fadaei R, et al. Preparation and evaluation of clinical effects of glucantime gel mask. Journal of Isfahan Medical School 2013;31(231):389-99. [EMBASE: 2014593999]2831986
62. Mujtaba G, Khalid M. Weekly vs. fortnightly intralesional meglumine antimoniate in cutaneous leishmaniasis. International Journal of Dermatology 1999;38(8):607-9. [PUBMED: 10487452]2831988
63. Nassiri-Kashani M, Firooz A, Khamesipour A, Mojtahed F, Nilforoushzadeh M, Hejazi H, et al. A randomized, double-blind, placebo-controlled clinical trial of itraconazole in the treatment of cutaneous leishmaniasis. Journal of the European Academy of Dermatology and Venereology: JEADV 2005;19(1):80-3. [PUBMED: 15649196]2831990
64. Nilforoushzadeh MA. Efficacy of combined triple therapy (paromomycin ointment, cryotherapy and intralesional Glucantime) in comparison with intralesional Glucantime for treatment of acute cutaneous leishmaniasis. Iranian Journal of Dermatology 2004;3(7):136-9. 2831992
65. Nilforoushzadeh MA, Jaffary F, Reiszadeh MR. Comparative effect of topical trichloroacetic acid and intralesional meglumine antimoniate in the treatment of acute cutaneous leishmaniasis. International Journal of Pharmacology 2006;2(6):633-6. [EMBASE: 2007084731]2831994
66. Nilforoushzadeh MA, Reiszadeh MR, Jafari F. Topical trichloroacetic acid compared with intralesional glucantime injection in the treatment of acute wet cutaneous leishmaniasis: An open clinical trial. Iranian Journal of Dermatology 2003;2(6):34-9. 2831995
67. Nilforoushzadeh MA, Jaffary F, Moradi S, Derakhshan R, Haftbaradaran E. Effect of topical honey application along with intralesional injection of glucantime in the treatment of cutanneous leishmaniasis. BMC Complementary and Alternative Medicine 2007;7:13. [PUBMED: 17466071]2831997
68. Nilforoushzadeh MA, Jaffary F, Ansari N, Siadat AH, Nilforoushan Z, Firouz A. A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis. Journal of Vector Borne Diseases 2008;45(4):287-91. [PUBMED: 19248655]2831999
69. Nilforoushzadeh MA, Naeeni FF, Sattar N, Haftbaradaran E, Jaffary F, Askari G. The effect of intralesional meglumine antimoniate (Glucantime) versus a combination of topical trichloroacetic acid 50% and local heat therapy by non-ablative radiofrequency on cutaneous leishmaniasis lesions. Journal of Research in Medical Sciences 2012;17(1 Suppl 1):S97-S102. [EMBASE: 2013471627]2832001
70. Nilforoushzadeh MA, Siadat AH, Ansari N, Haftbaradaran E, Ahmadi E. A comparison between the effects of glucantime, topical trichloroacetic acid 50% plus glucantime, and fractional laser plus glucantime on cutaneous leishmaniasis lesions. Journal of Isfahan Medical School 2013;30(221):2450-9. [EMBASE: 2013245548]2832003
71. Nilforoushzadeh MA, Siadat AH, Haftbaradaran E, Minaravesh M. Comparative study of the efficacy of CO2 and fraxel lasers in treatment of cutaneous leishmaniasis scars. Journal of Isfahan Medical School 2014;31(269 SPEC.ISSUE):2277-84. [EMBASE: 2014574591]7068480
72. Nilforoushzadeh MA, Jaffary F, Derakhsahan R, Haftbaradaran E. Comparison between intralesional meglumine antimoniate and combination of trichloroacetic acid 50% and intralesional meglumine antimoniate in the treatment of acute cutaneous leishmaniasis: a randomized clinical trial. Journal of Stem Cells 2014;1(1):e16633. [DOI: 10.5812/jssc.16633; EMBASE: 2015013267]7068482
73. Özgöztasi O, Baydar I. A randomized clinical trial of topical paromomycin versus oral ketoconazole for treating cutaneous leishmaniasis in Turkey. International Journal of Dermatology 1997;36(1):61-3. [EMBASE: 1997097334]2832009
74. Ranawaka RR, Weerakoon HS. Randomized, double-blind, comparative clinical trial on the efficacy and safety of intralesional sodium stibogluconate and intralesional 7% hypertonic sodium chloride against cutaneous leishmaniasis caused by L. donovani. Journal of Dermatological Treatment 2010;21(5):286-93. [PUBMED: 20438389]2832013
75. Ranawaka RR, Weerakoon HS, Silva SH. Randomized, double-blind, controlled, comparative study on intralesional 10% and 15% hypertonic saline versus intralesional sodium stibogluconate in Leishmania donovani cutaneous leishmaniasis. International Journal of Dermatology 2015;54(5):555-63. [PUBMED: 25600472]2832015
76. Reithinger R, Mohsen M, Wahid M, Bismullah M, Quinnell RJ, Davies CR, et al. Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial. Clinical Infectious Diseases 2005;40(8):1148-55. [PUBMED: 15791515]2832017
77. Sadeghian G, Nilforoushzadeh MA. Effect of combination therapy with systemic glucantime and pentoxifylline in the treatment of cutaneous leishmaniasis. International Journal of Dermatology 2006;45(7):819-21. [PUBMED: 16863518]7068484
78. Sadeghian G, Nilfroushzadeh MA, Siadat AH. A comparison between intralesional hypertonic sodium chloride solution and meglumine antimoniate in the treatment of cutaneous leishmaniasis. Egyptian Dermatology Online Journal 2;1:8. 2832021
79. Sadeghian G, Nilfroushzadeh MA, Iraji F. Efficacy of local heat therapy by radiofrequency in the treatment of cutaneous leishmaniasis, compared with intralesional injection of meglumine antimoniate. Clinical and Experimental Dermatology 2007;32(4):371-4. [PUBMED: 17376205]2832023
80. Safi N, Davis GD, Nadir M, Hamid H, Robert LL, Case AJ. Evaluation of thermotherapy for the treatment of cutaneous leishmaniasis in Kabul, Afghanistan: a randomized controlled trial. Military Medicine 2012;177(3):345-351. [PUBMED: 22479925]2832025
81. Salmanpour R, Handjani F, Nouhpisheh MK. Comparative study of the efficacy of oral ketoconazole with intra-lesional meglumine antimoniate (Glucantime) for the treatment of cutaneous leishmaniasis. Journal of Dermatological Treatment 2001;12:159-62. [PUBMED: 12243707 ]2832027
82. Salmanpour R, Razmavar MR, Abtahi N. Comparison of intralesional meglumine antimoniate, cryotherapy and their combination in the treatment of cutaneous leishmaniasis. International Journal of Dermatology 2006;45(9):1115-6. [PUBMED: 16961529]2832029
83. Shamsi Meymandi S, Zandi S, Aghaie H, Heshmatkhah A. Efficacy of CO(2) laser for treatment of anthroponotic cutaneous leishmaniasis, compared with combination of cryotherapy and intralesional meglumine antimoniate. Journal of the European Academy of Dermatology and Venereology: JEADV 2011;25(5):587-91. [PUBMED: 20666876]7068486
84. Shanehsaz SM, Ishkhanian S. A comparative study between the efficacy of oral cimetidine and low-dose systemic meglumine antimoniate (MA) with a standard dose of systemic MA in the treatment of cutaneous leishmaniasis. International Jornal of Dermatology 2015;54(7):834-8. [PUBMED: 26108265]2832035
85. Shanehsaz SM, Ishkhanian S. Therapeutic and adverse effects of standarddose and low-dose meglumine antimoniate during systemic treatment of Syrian cutaneous leishmaniasis patients. Journal of Pakistan Association of Dermatologists 2014;24(2):115-121. [EMBASE: 2014549292]7068487
86. Sharquie KE, Najim RA, Farjou IB. A compararive controlled trial of intralesionally- administered zinc sulphate, hypertonic sodium chloride and pentavalent antimony compound against cutaneous leishmaniasis. Clinical and Experimental Dermatology 1997;22(4):169-73. [PUBMED: 9499605]2832037
87. Sharquie KE, Najim RA, Farjou IB, Al-timimit DJ. Oral zinc sulphate in the treatment of acute cutaneous leishmaniasis. Clinical and Experimental Dermatology 2001;26(1):21-6. [PUBMED: 11260171]2832039
88. Shazad B, Abbaszadeh B, Khamesipour A. Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major. European Journal of Dermatology 2005;15(2):85-7. [PUBMED: 15757817]2832041
89. Stahl HC, Ahmadi F, Schleicher U, Sauerborn R, Bermejo JL, Amirih ML, et al. A randomized controlled phase IIb wound healing trial of cutaneous leishmaniasis ulcers with 0.045% pharmaceutical chlorite (DAC N-055) with and without bipolar high frequency electro-cauterization versus intralesional antimony in Afghanistan. BMC Infectious Diseases 2014;14:619. [PUBMED: 25420793]2832043
90. Yazdanpanah MJ, Banihashemi M, Pezeshkpoor F, Khajedaluee M, Famili S, Tavakoli Rodi I, et al. Comparison of oral zinc sulfate with systemic meglumine antimoniate in the treatment of cutaneous leishmaniasis. Dermatology Research & Practice 2011;269515:1-4. [DOI: 10.1155/2011/269515; PUBMED: 21747837]2832045
91. Zerehsaz F, Salmanpour R, Farhad H, Ardehali S, Panjehshahin MR, Tabei SZ, et al. A double-blind randomized clinical trial of a topical herbal extract (Z-HE) vs. systemic meglumine antimoniate for the treatment of cutaneous leishmaniasis in Iran. International Journal of Dermatology 1999;38(8):610-2. [PUBMED: 10487453]2832047
92. Alavi-Naini R, Fazaeli A, O'Dempsey T. Topical treatment modalities for old world cutaneous leishmaniasis: a review. Prague Medical Report 2012;113(2):105-18. [PUBMED: 22691282]2832049
93. Banihashemi M, Yazdanpanah MJ, Amirsolymani H, Yousefzadeh H. Comparison of lesion improvement in lupoid leishmaniasis patients with two treatment approaches: trichloroacetic Acid and intralesional meglumine antimoniate. Journal of Cutaneous Medicine and Surgery 2015;19(1):35-9. [PUBMED: 25775661]2832051
94. Bumb RA, Mehta RD, Ghiya BC, Jakhar R, Prasad N, Soni P, et al. Efficacy of short-duration (twice weekly) intralesional sodium stibogluconate in treatment of cutaneous Leishmaniasis in India. British Journal of Dermatology 2010;163(4):854-8. [PUBMED: 20500797]2832053
95. Dogra J, Lal BB, Misra SN. Dapsone in the treatment of cutaneous leishmaniasis. International Journal of Dermatology 1986;25(6):398-400. [PUBMED: 3531044]2832055
96. Dogra J, Aneja N. Leishmaniasis and itraconazole: a controlled clinical trial on cutaneous subtypes. International Journal of Antimicrobial Agents 1994;4(4):309-11. [PUBMED: 18611622]2832057
97. Dorlo TP, Balasegaram M, Beijnen JH, de Vries PJ. Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. Journal of Antimicrobial Chemotherapy 2012;67(11):2576-97. [PUBMED: 22833634 ]2832059
98. el-On J, Halevy S, Grunwald MH, Weinrauch L. Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: a double blind control study. Journal of the American Academy of Dermatology 1992;27(2 Pt 1):227-31. [PUBMED: 1430361]2832061
99. Frankenburg S, Gross A, Jonas F, Klaus S. Effect of topical paromomycin on cell-mediated immunity during cutaneous leishmaniasis. International Journal of Dermatology 1993;32(1):68-70. [PUBMED: 8425810]2832063
100. Kim DH, Chung HJ, Bleys J, Ghohestani RF. Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials. PLoS Neglected Tropical Diseases 2009;3(2):e381. [PUBMED: 19221595]2832065
101. Moosavi Z, Nakhli A, Rassaii S. Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis. International Journal of Dermatology 2005;44(12):1064-5. [PUBMED: 16409282]2832067
102. Ali NM, Fariba J, Elaheh H, Ali N. The efficacy of 5% trichoroacetic acid cream in the treatment of cutaneous leishmaniasis lesions. Journal of Dermatological Treatment 2012;23(2):136-9. [PUBMED: 21034291]2832069
103. Nilforoushzadeh MA, Jaffary F, Ansari N, Moradi S, Siadat AH. The comparison between trichloroacetic acid 50% and CO2 laser in the treatment of cutaneous leishmaniasis scar. Indian Journal of Dermatology 2011;56(2):171-3. [PUBMED: 21716542]2832071
104. Shanehsaz SM, Ishkhanian S. Electrocardiographic and biochemical adverse effects of meglumine antimoniate during the treatment of Syrian cutaneous leishmaniasis. Egyptian Dermatology Journal 2013;9(1):5. 2832075
105. Singh S, Singh R, Sundar S. Failure of ketaconazole in oriental sore in India. Journal of Chemotherapy 1995;7(4):202-3. [PUBMED: 8904156]2832077
106. Trau H, Schewach-Millet M, Shoham J, Doerner T, Shor R, Passwell JH. Topical application of human fibroblast interferon (IFN) in cutaneous leishmaniasis. Israel Journal of Medical Sciences 1987;23(11):1125-7. [PUBMED: 3325468]2832079
107. Farajzadeh S, Hakimi Parizi M, Haghdoost AA, Mohebbi A, Mohammadi S, Pardakhty A, et al. Comparison between intralesional injection of zinc sulfate 2 % solution and intralesional meglumine antimoniate in the treatment of acute old world dry type cutaneous leishmaniasis: a randomized double-blind clinical trial. Journal of Parasitic Diseases 2016;40(3):935-9. [PUBMED: 27605813]7068489
108. Farajzadeh S, Heshmatkhah A, Vares B, Mohebbi E, Mohebbi A, Aflatoonian M, et al. Topical terbinafine in the treatment of cutaneous leishmaniasis: triple blind randomized clinical trial. Journal of Parasitic Diseases 2016;40(4):1159-64. [DOI: 10.1007/s12639-014-0641-1; PUBMED: 27876906]7068491
109. Hanif MM, Akram K, Mustafa G. Intralesional versus oral chloroquine in cutaneous leishmaniasis: comparison of outcome, duration of treatment and total dose of drug. Journal of the College of Physicians and Surgeons Pakistan 2016;26(4):260-2. [PUBMED: 27097693]7068493
110. Jaffary F, Nilforoushzadeh MA, Siadat A, Haftbaradaran E, Ansari N, Ahmadi E. A comparison between the effects of Glucantime, topical trichloroacetic acid 50% plus Glucantime, and fractional carbon dioxide laser plus Glucantime on cutaneous leishmaniasis lesions. Dermatology Research and Practice 2016;2016:6462804. [PUBMED: 27148363]7068495
111. Na-Bangchang K, Ahmed O, Hussein J, Hirayama K, Kongjam P, Aseffa A, et al. Exploratory, phase II controlled trial of shiunko ointment local application twice a day for 4 weeks in Ethiopian patients with localized cutaneous leishmaniasis. Evidence-Based Complementary and Alternative Medicine 2016;2016:5984709. [PUBMED: 27195014]7068497
112. Rajabi O, Layegh P, Hashemzadeh S, Khoddami M. Topical liposomal azithromycin in the treatment of acute cutaneous leishmaniasis. Dermatologic Therapy 2016;29(5):358-63. [DOI: 10.1111/dth.12357; PUBMED: 27073044]7068499
113. Refai W, Madarasingha N, Weerasingha S, Senarath U, De Silva A, Fernandopulle R, et al. Efficacy, safety and cost-effectiveness of thermotherapy for L. donovani-induced cutaneous leishmaniasis: a randomized controlled clinical trial. International Journal of Infectious Diseases 2016;45:74. [CENTRAL: CN-01142616]7068501
114. Sattar FA, Ahmed F, Ahmed N, Sattar SA, Malghani MA, Choudhary MI. A double-blind, randomized, clinical trial on the antileishmanial activity of a Morinda citrifolia (Noni) stem extract and its major constituents. Natural Product Communications 2012;7(2):195-6. [PUBMED: 22474954]2832073
115. ACTRN12614001288617. A clinical trial to assess the safety and effect of heat therapy in comparison to standard intra-lesional sodium stibogluconate for cutaneous leishmaniasis [In patients with cutaneous leishmaniasis, thermotherapy was compared with standard intra-lesional therapy with regard to efficacy and safety]. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12614001288617 Date first received: 10 December 2014. 7068502
116. IRCT138904091159N7. Comparison between two groups in the treatment of cutaneous leishmaniasis [Comparison between the efficacy of intralesional placebo and nitric oxide releasing patch versus placebo patch and glucantime in the treatment of cutaneous leishmaniasis]. www.irct.ir/searchresult.php?id=1159&number=7 Date first received: 2 September 2013. 7068503
117. IRCT2013092414746N1. Treatment of patients with ZCL [The effect of MJ1 (Topical dairy extract) versus routine care for treatment of cutaneous leishmaniasis (rural) in Isfahan Iran :a randomized controled clinical trial (RCTs) -]. apps.who.int/trialsearch/Trial2.aspx?TrialID=IRCT2013092414746N1 Date first received: 20 February 2014. 7068504
118. NCT00840359. Study of the Efficacy of Daylight Activated Photodynamic Therapy in the Treatment of Cutaneous Leishmaniasis [Phase 2 Study of the Efficacy of Daylight Activated Photodynamic Therapy in the Treatment of Cutaneous Leishmaniasis]. clinicaltrials.gov/ct2/show/NCT00840359 Date first received: 8 February 2009. 7068505
119. NCT01050777. Efficacy of Topical Liposomal Form of Drugs in Cutaneous Leishmaniasis [Pilot Study of Efficacy of Topical Nano-liposomal Meglumine Antimoniate (Glucantime) or Paromomycin in Combination With Systemic Glucantime for the Treatment of Anthroponotic Cutaneous Leishmaniasis (ACL) Caused by Leishmania Tropica]. clinicaltrials.gov/ct2/show/NCT01050777 Date first received: 13 January 2010. 7068506
120. SLCTR/2014/028. Treatment for leishmaniasis [Randomized, double blind, controlled study on efficacy and safety of intralesional metronidazole vs intralesional sodium stibogluconate in L. donovani cutaneous leishmaniasis]. slctr.lk/trials/276 Date first received: 18 October 2014. 7068507
121. Adam I, Elhardello OA, Elhadi MO, Abdalla E, Elmardi KA, Jansen FH. The antischistosomal efficacies of artesunate-sulfamethoxypyrazine-pyrimethamine and artemether-lumefantrine administered as treatment for uncomplicated Plasmodium falciparum malaria. Annals of Tropical Medicine and Parasitology 2008;102(1):39-44. [PUBMED: 18186976]
122. Al-Waiz M, Sharquie KE, Al-Assir M. Treatment of cutaneous leishmaniasis by intralesional metronidazole. Saudi Medical Journal 2004;25(10):1512-3. [PUBMED: 15494841]
123. Alrajhi AA. Cutaneous leishmaniasis of the Old World. Skin Therapy Letter 2003;8(2):1-4. [PUBMED: 12728282]
124. Alvar J, Yactayo S, Bern C. Leishmaniasis and poverty. Trends in Parasitology 2006;22(12):552-7. [PUBMED: 17023215]
125. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 2012;7(5):e35671. [PUBMED: 22693548]
126. Amin SP, Phelps RG, Goldberg DJ. Mesotherapy for facial skin rejuvenation: a clinical, histologic, and electron microscopic evaluation. Dermatologic Surgery 2006;32(12):1467-1472. [PUBMED: 17199654]
127. Aram H, Leibovici V. Ultrasound-induced hyperthermia in the treatment of cutaneous leishmaniasis. Cutis 1987;40(4):350-3. [PUBMED: 3677796]
128. Arevalo I, Tulliano G, Quispe A, Spaeth G, Mathlashewski, Llanos-cuantas A, et al. Role of imiquimod and parenteral meglumine antimoniate in the intitial treatment of cutaneous lesihmaniasis. Clinical Infectious Diseases 2007;44(12):1549-54. [PUBMED: 17516397]
129. Babajev KB, Babajev OG, Korepanov VI. Treatment of cutaneous leishmaniasis using a carbon dioxide laser. Bulletin of the World Health Organization 1991;69(1):103-6. [PUBMED: 1905204]
130. Badaro R, Falcoff E, Badaro FS, Carvalho EM, Pedral-Sampaio D, Barral A, et al. Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. New England Journal of Medicine 1990;322(1):16-21. [PUBMED: 2104665]
131. Baryza MJ, Baryza GA. The Vancouver Scar Scale: an administration tool and its interrater reliability. Journal of Burn Care Rehabilitation 1995;16(5):535-8. [PUBMED: 8537427]
132. Bassiouny A, El Meshad M, Talaat M, Kutty K, Metawaa B. Cryosurgery in cutaneous leishmaniasis. British Journal of Dermatology 1982;107(4):467-74. [PUBMED: 7126453]
133. Berman JD, Neva FA. Effect of temperature on multiplication of Leishmania amastigotes within monocyte-derived macrophages in vitro. American Journal of Tropical Medicine and Hygiene 1981;30(2):318-21. [PUBMED: 7235124]
134. Bigby M, Williams H. Appraising Systematic Reviews and Meta-analyses. Archives of Dermatology 2003;139(6):795-798. [PUBMED: 12810513]
135. Blum J, Lockwood DN, Visser L, Harms G, Bailey MS, Caumes E, et al. Local or systemic treatment for New World cutaneous leishmaniasis? Re-evaluating the evidence for the risk of mucosal leishmaniasis. International Health 2012;4(3):153-63. [PUBMED: 24029394]
136. Blum J, Buffet P, Visser L, Harms G, Bailey MS, Caumes E, et al. LeishMan recommendations for treatment of cutaneous and mucosal leishmaniasis in travelers, 2014. Journal of Travel Medicine 2014;21(2):116-29. [PUBMED: 24745041]
137. Bogenrieder T, Lehn N, Landthaler M, Stolz W. Treatment of Old World cutaneous leishmaniasis with intralesionally injected meglumine antimoniate using a Dermojet device. Dermatology 2003;206(3):269-72. [PUBMED: 12673089]
138. Borelli D. A clinical trial of itraconazole in the treatment of deep mycoses and leishmaniasis. Reviews of Infectious Diseases 1987;9(Suppl 1):S57-63. [PUBMED: 3027848]
139. Bryceson AD, Murphy A, Moody AH. Treatment of 'Old World' cutaneous leishmaniasis with aminosidine ointment: results of an open study in London. Transactions of the Royal Society of Tropical Medicine and Hygiene 1994;88(2):226-8. [PUBMED: 8036683]
140. Bygbjerg IC, Knudsen L, Kieffer M. Failure of rifampicin therapy to cure cutaneous leishmaniasis. Archives of Dermatology 1980;116(9):988. [PUBMED: 7416770]
141. Cardo LJ. Leishmania: risk to the blood supply. Transfusion 2006;46(9):1641-45. [PUBMED: 16965594]
142. Cauwenberg G, De Doncker P. Itraconazole (R 51 211): a clinical review of its anti mycotic activity in dermatology, gynecology, and internal medicine. Drug Development Research 1986;8:317-23. [DOI: 10.1002/ddr.430080136]
143. Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. Lancet 2009;374(9683):86-9. [PUBMED: 19525005]
144. Chunge CN, Gachihi G, Muigai R, Wasunna K, Rashid JR, Chulay JD, et al. Visceral leishmaniasis unresponsive to antimonial drugs. III. Successful treatment using a combination of sodium stibogluconate plus allopurinol. Transactions of the Royal Society of Tropical Medicine and Hygiene 1985;79(5):715-8. [PUBMED: 3006296]
145. Crawford R, Holmes D, Meymandi S. Comparative study of the efficacy of combined imiquimod 5% cream and intralesional meglumine antimoniate versus imiquimod 5% cream and intralesional meglumine antimoniate alone for the treatment of cutaneous leishmaniasis. Journal of the American Academy of Dermatology 2005;52:S118.
146. Croft SL, Seifert K, Yardley V. Current scenario of drug development for Leishmaniasis. Indian Journal of Medical Research 2006;123(3):399-410. [PUBMED: 16778319]
147. Daie Parizi MH. Treatment of cutaneous leishmaniasis with local application of the tincture of Thioxolone and benzoxonium chloride (first research in the world) at annual congress of Iranian society of pediatrics, Tehran, Iran, Oct 1992. The Annual Book of Congress 1992;1:121-5.
148. Daie Parizi MH, Shamsaddini S. Comparison between topical treatment with Thioxolone, Benzoxonium Chloride tincture and intralesional injection of Meglumine Antimoniate on cutaneous Leishmaniasis. Journal of Kerman University of Medical Sciences 1996;3(1):7-14.
149. Davies CR, Kaye P, Croft SL, Sundar S. Leishmaniasis: new approaches to disease control. BMJ 2003;326(7385):377-82. [PUBMED: 12586674 ]
150. de Vries HJ, Reedijk SH, Schallig HD. Cutaneous leishmaniasis: recent developments in diagnosis and management. American Journal of Clinical Dermatology 2015;16(2):99-109. [PUBMED: 25687688]
151. Delamere FM, Sladden MJ, Dobbins HM, Leonardi-Bee J. Interventions for alopecia areata. Cochrane Database of Systematic Reviews 2008;2:CD004413. [DOI: 10.1002/14651858.CD004413.pub2]
152. den Boer M, Argaw D, Jannin J, Alvar J. Leishmaniasis impact and treatment access. Clinical Microbiology and Infection 2011;17(10):1471-7. [PUBMED: 21933305]
153. Desjeux P. Leishmaniasis. Public health aspects and control. Clinical Dermatology 1996;14(5):417-23. [PUBMED: 8889319]
154. Dorlo TP, van Thiel PP, Schoone GJ, Stienstra Y, van Vugt M, Beijnen JH, et al. Dynamics of parasite clearance in cutaneous leishmaniasis patients treated with miltefosine. PLoS Neglected Tropical Diseases 2011;5(12):e1436. [PUBMED: 22180803]
155. Egger M, Davey Smith G, Schneider M, Minder C. Biasin meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34. [PUBMED: 9310563]
156. el-On J, Weinrauch L, Livshin R, Even-Paz Z, Jacobs GP. Topical treatment of recurrent cutaneous leishmaniasis with ointment containing paromomycin and methylbenzethonium chloride. British Medical Journal (Clinical Research Ed.) 1985;291(6497):704-5. [PUBMED: 3929905]
157. el-Safi SH, Murphy AG, Bryceson AD, Neal RA. A double-blind clinical trial of the treatment of cutaneous leishmaniasis with paromomycin ointment. Transactions of the Royal Society of Tropical Medicine and Hygiene 1990;84(5):690-1. [PUBMED: 2278070]
158. Faber WR, Oskam L, van Gool T, Kroon NC, Knegt-Junk KJ, Hofwegen H, et al. Value of diagnostic techniques for cutaneous leishmaniasis. Journal of the American Academy of Dermatology 2003;49(1):70-4. [PUBMED: 12833011]
159. Fatima F, Khalid A, Nazar N, Abdalla M, Mohomed H, Toum AM, et al. In vitro assessment of anti - cutaneous leishmaniasis activity of some Sudanese plants. Turkiye Parazitoloji Dergisi 2005;29(1):3-6. [PUBMED: 17167733]
160. US Food, Drugs Administration. News and Events - FDA News Release 2014. www.fda.gov/NewsEvents/Newsroom/PrressAnnouncements/ucm389671.htm (acessed prior to 10 October 2016).
161. Garnier T, Croft SL. Topical treatment for cutaneous leishmaniasis. Current Opinion in Investigational Drugs (London, England: 2000) 2002;3(4):538-44. [PUBMED: 12090720]
162. González U, Pinart M, Rengifo-Pardo M, Macaya A, Alvar J, Tweed JA. Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD004834.pub2]
163. González U, Pinart M, Reveiz L, Rengifo-Pardo M, Tweed J, Macaya A, et al. Designing and reporting clinical trials on treatments for cutaneous leishmaniasis. Clinical Infectious Diseases 2010;51(4):409-19. [PUBMED: 20624067]
164. González U, Pinart M, Sinclair D, Firooz A, Enk C, Vélez ID, et al. Vector and reservoir control for preventing leishmaniasis. Cochrane Database of Systematic Reviews 2015, Issue 8. [DOI: 10.1002/14651858.CD008736.pub2]
165. Goodman AC. Beware the "Texas sharp shooter" in rate ratios of progression. BMJ 2007;334(7591):440. [PUBMED: 17332546]
166. Gradoni L, López-Vélez R, Mokni M. World Health Organization. Manual on case management and surveillance of the leishmaniasis in the WHO European Region. www.who.int/leishmaniasis/resources/EURO_WHO_Leish_manual_on_case_management_and_surveillance:9789289052511_2017.pdf?ua=1 (accessed prior to 15 November 2017).
167. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6. [PUBMED: 18436948]
168. Hepburn NC. Management of cutaneous leishmaniasis. Current Opinion in Infectious Diseases 2001;14(2):151-4. [PUBMED: 11979125]
169. Herwaldt BL. Leishmaniasis. Lancet 1999;354(9185):1191-9. [PUBMED: 10513726]
170. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. [PUBMED: 12958120]
171. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928. [PUBMED: 22008217]
172. Ingram JR, Woo PN, Chua SL, Ormerod AD, Desai N, Kai AC, et al. Interventions for hidradenitis suppurativa. Cochrane Database of Systematic Reviews 2015, Issue 10. [DOI: 10.1002/14651858.CD010081.pub2]
173. Jha TK. Evaluation of allopurinol in the treatment of kala-azar occurring in North Bihar, India. Transactions of the Royal Society of Tropical Medicine and Hygiene 1983;77(2):204-7. [PUBMED: 6868102]
174. Jiang S, Meadows J, Anderson SA, Mukkada AJ. Antileishmanial activity of the antiulcer agent omeprazole. Antimicrobial agents and chemotherapy 2002;46(8):2569-74. [PUBMED: 12121934]
175. Junaid AJ. Treatment of cutaneous leishmaniasis with infrared heat. International Journal of Dermatology 1986;25(7):470-2. [PUBMED: 3771049]
176. Kager PA, Rees PH, Wellde BT, Hockmeyer WT, Lyerly WH. Allopurinol in the treatment of visceral leishmaniasis. Transactions of the Royal Society of Tropical Medicine and Hygiene 1981;75(4):556-9. [PUBMED: 6275579]
177. Karamian M, Motazedian MH, Mehrabani D, Gholami K. Leishmania major infection in a patient with visceral leishmaniasis: treatment with Amphotericin B. Parasitology Research 2007;101(5):1431-4. [PUBMED: 17659388]
178. Keiser J, Utzinger J. Artemisinins and synthetic trioxolanes in the treatment of helminth infections. Current Opinion in Infectious Diseases 2007;20(6):605-12. [PUBMED: 17975411]
179. Kermode M. Unsafe injections in low-income country health settings: need for injection safety promotion to prevent the spread of blood-borne viruses. Health Promotion International 2004;19(1):95-103. [PUBMED: 14976177]
180. Fatima F, Khalid A, Nazar N, Abdalla M, Mohomed H, Toum AM, et al. In vitro assessment of anti -cutaneous leishmaniasis activity of some Sudanese plants. Türkiye Parazitoloji Dergisi 2005;29(1):3-6. [PUBMED: 17167733]
181. Khatami A, Firooz A, Gorouhi F, Dowlati Y. Treatment of acute Old World cutaneous leishmaniasis: a systematic review of the randomized controlled trials. Journal of the American Academy of Dermatology 2007;57(2):335.e1-29. [PUBMED: 17337090]
182. Laguna F, López-Vélez R, Pulido F, Salas A, Torre-Cisneros J, Torres E, et al. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group. AIDS 1999;13(9):1063-9. [PUBMED: 10397536]
183. Leibovici V, Aram H. Cryotherapy in acute cutaneous leishmaniasis. International Journal of Dermatology 1986;25(7):473-5. [PUBMED: 3533799]
184. Lessa HA, Machado P, Lima F, Cruz AA, Bacellar O, Guerreiro J, et al. Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony. American Journal of Tropical Medicine and Hygiene 2001;65(2):87-9. [PUBMED: 11508396]
185. Mapar MA, Kavoosi H, Dabbagh MA. Assessment of the effect of topical opium in treatment of cutaneous leishmaniasis. Iranian Journal of Dermatology 2001;4(16):23-8.
186. Masmoudi A, Hariz W, Marrekchi S, Amouri M, Turki H. Old World cutaneous leishmaniasis: diagnosis and treatment. Journal of Dermatological Case Reports 2013;7(2):31-41. [PUBMED: 23858338]
187. Meawad OB. Selective heat therapy in cutaneous leishmaniasis: a preliminary experience using the 585 nm pulsed dye laser. Journal of the European Academy of Dermatology and Venereology: JEADV 1997;8(3):241-4. [EMBASE: 27286057]
188. Migdal C, Serres M. Reactive oxygen species and oxidative stress. Medical Science 2011;27(4):405-412. [PUBMED: 21524406]
189. Minodier P, Parola P. Cutaneous leishmaniasis treatment. Travel Medicine and Infectious Disease 2007;5(3):150-8. [PUBMED: 17448941]
190. Modabber F, Buffet PA, Torreele E, Milon G, Croft SL. Consultative meeting to develop a strategy for treatment of cutaneous leishmaniasis. Institute Pasteur, Paris. 13-15 June, 2006. Kinetoplastid Biology and Disease 2007;6:3. [PUBMED: 17456237]
191. Monge-Maillo B, López-Vélez R. Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis. Drugs 2013;73(17):1889-920. [PUBMED: 24170665]
192. Monge-Maillo B, López-Vélez R. Miltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendations. Clinical Infectious Diseases 2015;60(9):1398-404. [PUBMED: 25601455]
193. Moore OA, Smith LA, Campbell F, Seers K, McQuay KJ, Moore RA. Systematic review of the use of honey as a wound dressing. BMC Complementary and Alternative Medicine 2001;1:2. [PUBMED: 11405898]
194. Moskowitz PF, Kurban AK. Treatment of cutaneous leishmaniasis: Retrospective and advances for the 21st century. Clinical Dermatology 1999;17(3):305-15. [PUBMED: 10384870]
195. Mosleh IM, Geith E, Natsheh L, Schönian G, Abotteen N, Kharabsheh S. Efficacy of a weekly cryotherapy regimen to treat Leishmania major cutaneous leishmaniasis. Journal of the American Academy of Dermatology 2008;58(4):617-24. [PUBMED: 18249466]
196. Munir A, Janjua SA, Hussain I. Clinical efficacy of intramuscular meglumine antimoniate alone and in combination with intralesional meglumine antimoniate in the treatment of old world cutaneous leishmaniasis. Acta Dermatovenerologica Croatica: ADC 2008;16(2):60-4. [PUBMED: 18541100]
197. Musa AM, Khalil EA, Mahgoub FA, Hamad S, Elkadaru AM, El Hassan AM. Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL). Annals of Tropical Medicine and Parasitology 2005;99(6):563-9. [PUBMED: 16156969]
198. Najim RA, Sharquie KE, Farjou IB. Zinc sulphate in the treatment of cutaneous leishmaniasis: an in vitro and animal study. Memórias do Instituto Oswaldo Cruz 1998;93(6):831-7. [PUBMED: 9921312]
199. Neva FA, Petersen EA, Corsey R, Bogaert H, Martinez D. Observations on local heat treatment for cutaneous leishmaniasis. American Journal of Tropical Medicine and Hygiene 1984;33(5):800-4. [PUBMED: 6091468]
200. Olliaro P, Vaillant M, Arana B, Grogl M, Modabber F, Magill A, et al. Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasis. PLoS Neglected Tropical Diseases 2013;7(3):e2130. [PUBMED: 23556016]
201. Pace D. Leishmaniasis. Journal of Infection 2014;69(Suppl 1):S10-S18. [PUBMED: 25238669]
202. Passwell JH, Shor R, Shoham J. The enhancing effect of interferon-beta and -gamma on the killing of Leishmania tropica major in human mononuclear phagocytes in vitro. Journal of Immunology 1986;136(8):3062-6. [PUBMED: 3082979]
203. Pieper B, Caliri MH. Nontraditional wound care: A review of the evidence for the use of sugar, papaya/papain, and fatty acids. Journal of Wound, Ostomy, and Continence Nursing 2003;30(4):175-83. [PUBMED: 12851592]
204. Pigott DM, Golding N, Messina JP, Battle KE, Duda KA, Balard Y, et al. Global database of leishmaniasis occurrence locations, 1960-2012. Scientific Data 2014;30(1):140036. [PUBMED: 25984344]
205. Ponte-Sucre A. Physiological consequences of drug resistance in Leishmania and their relevance for chemotherapy. Kinetoplastid Biology and Disease 2003;2(1):14. [PUBMED: 14613496]
206. Ranawaka RR, Weerakoon HS, Opathella N. Liquid nitrogen cryotherapy on Leishmania donovani cutaneous leishmaniasis. Journal of Dermatological Treatment 2011;22(4):241-5. [PUBMED: 20818996]
207. Rathi SK, Pandhi RK, Chopra P, Khanna N. Post-kala-azar dermal leishmaniasis: a histopathological study. Indian Journal of Dermatology, Venereology and Leprology 2005;71(4):250-53. [PUBMED: 16394433]
208. Reithinger R, Aadil K, Kolaczinski J, Mohsen M, Hami S. Social impact of leishmaniasis, Afghanistan. Emerging Infectious Diseases 2005;11(4):634-6. [PUBMED: 15834984]
209. Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S. Cutaneous leishmaniasis. Lancet Infectious Diseases 2007;7(9):581-96. [PUBMED: 17714672]
210. Rodriguez ME, Inguanzo P, Ramos A, Perez J. Treatment of cutaneous leishmaniasis with CO2 laser radiation. Revista Cubana de Medicina Tropical 1990;42(2):197-202. [PUBMED: 2128547]
211. Rodriguez-Cuartero A, Pérez-Blanco FJ, López-Fernández A. Co-trimoxazole for visceral leishmaniasis. Infection 1990;18(1):40. [PUBMED: 2312176]
212. Rohrich RJ, Janis EJ, Reisman NR. Use of off-label and non-approved drugs and devices in plastic surgery. Plastic and Reconstructive Surgery 2003;112(1):241-243. [PUBMED: 12832901]
213. Saab M, El Hage H, Charafeddine K, Habib RH, Khalifeh I. Diagnosis of cutaneous leishmaniasis: why punch when you can scrape?. American Journal of Tropical Medicine and Hygiene 2015;92(3):518-22. [PUBMED: 25561563]
214. Sacks DL, Barral A, Neva F. Thermosensitivity patterns of Old vs. New World cutaneous strains of Leishmania growing within mouse peritoneal macrophages in vitro. American Journal of Tropical Medicine and Hygiene 1983;32(2):300-4. [PUBMED: 6837841]
215. Sampaio SA, Godoy JT, Paiva L, Dillon NL, da Lacaz CS. The treatment of American (mucocutaneous) leishmaniasis with amphotericin B. Archives of Dermatology 1960;82:627-35. [PUBMED: 13745957]
216. Sampaio RN, Marsden PD. Treatment of the mucosal form of leishmaniasis without response to glucantime, with liposomal amphotericin B. Revista da Sociedade Brasileira de Medicina Tropical 1997;30(2):125-8. [PUBMED: 9148335]
217. Savioli L, Engels D, Daumerie D, Jannin J, Alvar J, Asiedu K, et al. Response from Savioli and colleagues from the Department of Neglected Tropical Diseases, World Health Organization. PLoS medicine 2006;3(6):e283. [PUBMED: 16789805]
218. Schallig HD, Oskam L. Molecular biological applications in the diagnosis and control of leishmaniasis and parasite identification. Tropical Medicine and International Health 2002;7(8):641-51. [PUBMED: 12167091]
219. Schmidt-Ott R, Klenner T, Overath P, Aebischer T. Topical treatment with hexadecylphosphocholine (Miltex) efficiently reduces parasite burden in experimental cutaneous leishmaniasis. Transactions of the Royal Society of Tropical Medicine and Hygiene 1999;93(1):85-90. [PUBMED: 10492799]
220. Schork MA, Ramington RD. The determination of sample size in disease studies in which drop out or non-adherence is a problem. Journal of Chronic Diseases 1967;20(4):233-9. [PUBMED: 6023231]
221. Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomized trials. Annals of Internal Medicine 2010;152(11):726-32. [DOI: 10.7326/0003-4819-152-11-201006010-00232]
222. Sharifi I, Fekri AR, Aflatoonian MR, Khamesipour A, Mahboudi F, Dowlati Y, et al. Leishmaniasis recidivans among school children in Bam, South-east Iran, 1994-2006. International Journal of Dermatology 2010;49(5):557-561. [PUBMED: 20534092]
223. Sharquie KE, Al-Talib K, Chu AC. Intralesional therapy of cutaneous leishmaniasis with sodium stibogluconate antimony. British Journal of Dermatology 1988;119(1):53-7. [PUBMED: 2841964]
224. Sharquie KE. A new intralesional therapy for cutaneousd leishmaniasis with hypertonic sodium chloride solution. Journal of Dermatology 1995;22(10):732-7. [PUBMED: 8586751]
225. Sharquie KE, Al-Azzawi KE. Intralesional therapy for cutaneous leishmaniasis with 2% zinc sulfate solution. Journal of Pan-Arab League of Dermatologists 1996;7:41-6.
226. Sharquie KE, Al-Hamamy H, El-Yassin D. Treatment of cutaneous leishmaniasis by direct current electrotherapy: the Baghdadin device. Journal of Dermatology 1998;25(4):234-7. [PUBMED: 9609980]
227. Simonsen L, Kane A, Lloyd J, Zaffran M, Kane M. Unsafe injections in the developing world and transmission of bloodborne pathogens: a review. Bulletin of the World Health Organization 1999;77(10):789-800. [PUBMED: 10593026]
228. Sindermann H, Engel J. Development of miltefosine as an oral treatment for leishmaniasis. Transactions of the Royal Society of Tropical Medicine and Hygiene 2006;100(Suppl 1):S17-20. [PUBMED: 16730362]
229. Solomon M, Pavlotsky F, Leshem E, Ephros M, Trau H, Schwartz E. Liposomal amphotericin B treatment of cutaneous leishmaniasis due to Leishmania tropica. Journal of the European Academy of Dermatology and Venereology 2011;25(8):973-7. [PUBMED: 21129042]
230. Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, et al. Miltefosine for new world cutaneous leishmaniasis. Clinical Infectious Diseases 2004;38(9):1266-72. [PUBMED: 15127339]
231. Stojkovic M, Junghanss T, Krause E, Davidson RN. First case of typical Old World cutaneous leishmaniasis treated with miltefosine. International Journal of Dermatology 2007;46(4):385-7. [PUBMED: 17442078]
232. Storer E, Wayte J. Cutaneous leishmaniasis in Afghani refugees. Australasian Journal of Dermatology 2005;46(2):80-3. [PUBMED: 15842398]
233. Stotland M, Shalita AR, Kissling RF. Dapsone 5% gel: a review of its efficacy and safety in the treatment of acne vulgaris. American Journal of Clinical Dermatology 2009;10(4):221-7. [PUBMED: 19489655]
234. Sundar S, Chakravarty J, Rai VK, Agrawal N, Singh SP, Chauhan V, et al. Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions. Clinical infectious Diseases 2007;45(5):556-61. [PUBMED: 17682988]
235. Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK. Injectable paromomycin for Visceral leishmaniasis in India. New England Journal of Medicine 2007;356(25):2571-81. [PUBMED: 17582067]
236. Thakur CP, Pandey AK, Sinha GP, Roy S, Behbehani K, Olliaro P. Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study. Transactions of the Royal Society of Tropical Medicine and Hygiene 1996;90(3):319-22. [PUBMED: 8758093]
237. Urcayo FG, Zaias N. Oral ketoconazole in the treatment of cutaneous leishmaniasis. International Journal of Dermatology 1982;21(7):414-6. [PUBMED: 6290403]
238. Uzun S, Durdu M, Culha G, Allahverdiyev AM, Memisoglu HR. Clinical features, epidemiology, and efficacy and safety of intralesional antimony treatment of cutaneous leishmaniasis: recent experience in Turkey. Journal of Parasitology 2004;90(4):853-9. [PUBMED: 15357081]
239. van Griensven J, Carrillo E, López-Vélez R, Lynen L, Moreno J. Leishmaniasis in immunosuppressed individuals. Clinical Microbiology and Infection 2014;20(4):286-299. [PUBMED: 24450618]
240. van Zuuren EJ, Fedorowicz Z, Carter B, van der Linden MMD, Charland L. Interventions for rosacea. Cochrane Database of Systematic Reviews 2015, Issue 4. [DOI: 10.1002/14651858.CD003262.pub5]
241. Vaneau M, Chaby G, Guillot B, Martel P, Senet P, Téot L, et al. Consensus panel recommendations for chronic and acute wound dressings. Archives of Dermatology 2007;143(10):1291-4. [PUBMED: 17938343]
242. Vardy D, Barenholz Y, Naftoliev N, Klaus S, Gilead L, Frankenburg S. Efficacious topical treatment for human cutaneous leishmaniasis with ethanolic lipid amphotericin B. Transactions of the Royal Society of Tropical Medicine and Hygiene 2001;95(2):184-6. [PUBMED: 11355557]
243. Weigel MM, Armijos RX. The traditional and conventional medical treatment of cutaneous leishmaniasis in rural Ecuador. Revista Panamericana de Salud Publica [Pan American Journal of Public Health] 2001;10(6):395-404. [PUBMED: 11820108]
244. Weinrauch L, Livshin R, El-On J. Cutaneous leishmaniasis treatment with ketoconazole. Cutis 1983;32(3):288-90, 294. [PUBMED: 6313298]
245. Weinrauch L, Livshin R, Even-Paz Z, El-On J. Efficacy of ketoconazole in cutaneous leishmaniasis. Archives of Dermatology 1983;275(5):353-4. [PUBMED: 6318670]
246. World Health Organization (WHO). Leishmaniasis. World Health Report 2002. www.who.int/whr/2002/annex/en/ (accessed 2 April 2004).
247. World Health Organization (WHO). Control of leishmaniasis. Report by the Secretariat 22 March 2007. apps.who.int/gb/archive/pdf_files/WHA60/A60_10-en.pdf (accessed before 11 October 2016).
248. World Health Organization (WHO). Report of the Fifth Consultative Meeting on Leishmania/HIV Co-infection. Addis Ababa, Ethiopia, 20-22 March 2007. www.who.int/leishmaniasis/resources/Leishmaniasis_hiv_coinfection5.pdf (accessed before 11 October 2016). [WHO/CDS/NTD/IDM/2007.5]
249. World Health Organization (WHO). Control of the leishmaniases: report of a meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva 22-26 March 2010. WHO technical report series 949. apps.who.int/iris/bitstream/10665/44412/1/WHO_TRS_949_eng.pdf (accessed before 11 October 2016). [ISBN 9789241209496 ]
250. World Health Organization (WHO). Application for Inclusion of Miltefosina on WHO Model List of Essential Medicines. Submitted to the EML Secretariat for consideration. November 2010. www.who.int/selection_medicines/committees/expert/18/applications/Miltefosine_application.pdf (accessed 11 October 2016).
251. Wortmann G, Zapor M, Ressner R, Fraser S, Hartzell J, Pierson J, et al. Lipsosomal amphotericin B for treatment of cutaneous leishmaniasis. American Journal of Tropical Medicine and Hygiene 2010;83(5):1028-33. [PUBMED: 21036832]
252. Zakraoui H, Ben Salah A, Ftaiti A, Marrakchi H, Zaatour A, Zaafouri B, et al. Spontaneous course of lesions of Leishmania major cutaneous leishmaniasis in Tunisia. Annales de Dermatologie et Venereogie 1995;122(6-7):405-7. [PUBMED: 8526421]
253. Zanger P, Kotter I, Raible A, Gelanew T, Schonian G, Kremsner PG. Case report: Successful treatment of cutaneous leishmaniasis caused by Leishmania aethiopica with liposomal amphothericin B in an immunocompromised traveler returning from Eritrea. American Journal of Tropical Medicine and Hygiene 2011;84(5):692-4. [PUBMED: 21540377]
254. Zeglin O. Infectiology and Tropical Dermatology Part 17: cutaneous leishmaniasis - a casuistry with after assessment [Infektiologie und Tropendermatologie - Teil 17: kutaneleishmaniasis - eine kasuistik mit nachbegutachtung]. Dermatology 2009;15(4):246ff.
255. González U, Pinart M, Reveiz L, Alvar J. Interventions for Old World cutaneous leishmaniasis. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD005067.pub3]